Bernd Goergen

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using LiMAx®, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver. Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis. At present, more than 20 studies regarding new indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options. These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests. The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.

Fiagon - Image Guidance Reimagined For easy navigation of instruments for ENT, BRAIN and SPINE Surgery. Just like a navigation system in a car, our system guides surgical instruments along a planned operation path, and thus improves the safety, speed and quality of the operation. Fiagon's unique latest-generation navigation system uses electromagnetic tracking matrix algorithms and the world's first flexible pointer technology. The user can bend these instruments without interfering with precision, as we are able to place our microsensors into the tip of the instruments. Imprint: Fiagon AG Medical Technologies Neuendorfstraße 23b 16761 Hennigsdorf Germany Tel. +49 3302 201 21 10 Fax +49 3302 201 21 15 info@fiagon.com www.fiagon.com Management Board: Prof. Dr.-Ing. Kai Desinger, Dr. Dirk Mucha, Dr. Friedrich Jacobi Chairman of the Supervisory Board: Prof. Dr. Walter L. Rust Registration: Headquarters: Hennigsdorf Registration court: Amtsgericht Neuruppin Registration Number: HRB 10738 V.A.T. No. DE256937496 Notice of liability: Fiagon AG Medical Technologies is not responsible for the content of linked external websites.

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using LiMAx®, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver. Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis. At present, more than 20 studies regarding new indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options. These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests. The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.

Fiagon - Image Guidance Reimagined For easy navigation of instruments for ENT, BRAIN and SPINE Surgery. Just like a navigation system in a car, our system guides surgical instruments along a planned operation path, and thus improves the safety, speed and quality of the operation. Fiagon's unique latest-generation navigation system uses electromagnetic tracking matrix algorithms and the world's first flexible pointer technology. The user can bend these instruments without interfering with precision, as we are able to place our microsensors into the tip of the instruments. Imprint: Fiagon AG Medical Technologies Neuendorfstraße 23b 16761 Hennigsdorf Germany Tel. +49 3302 201 21 10 Fax +49 3302 201 21 15 info@fiagon.com www.fiagon.com Management Board: Prof. Dr.-Ing. Kai Desinger, Dr. Dirk Mucha, Dr. Friedrich Jacobi Chairman of the Supervisory Board: Prof. Dr. Walter L. Rust Registration: Headquarters: Hennigsdorf Registration court: Amtsgericht Neuruppin Registration Number: HRB 10738 V.A.T. No. DE256937496 Notice of liability: Fiagon AG Medical Technologies is not responsible for the content of linked external websites.

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed approx. 800 start-ups and successfully sold shares in 200 companies. HTGF has over 2 billion euros of fund volume. Fund investors in the public-private partnership include the German Federal Ministry of Economics and Energy, KfW Capital and 45 companies.

DZ BANK is the second largest bank in Germany. It is the central institution in the cooperative financial network and serves around 700 cooperative banks, each of which is a stakeholder in DZ BANK AG and which together own the majority stake. As “DZ BANK. Die Initiativbank”, it is also active as a corporate bank and is the holding company for the specialised service providers in the DZ BANK Group: Bausparkasse Schwäbisch Hall (building society), DZ HYP (real estate and public sector financing), DZ PRIVATBANK, R+V Versicherung (insurance company), TeamBank (consumer finance), Union Investment Group (asset management), VR Smart Finanz and various other specialised institutions. With its extensive range of financial products and services, the DZ BANK Group supports the local cooperative banks in Retail Banking, Corporate Banking, Capital Markets and Transaction Banking. Find out more: www.dzbank.com Impressum: http://www.impressum.dzbank.de Datenschutz: http://www.dzbank.de/datenschutz-social-media